Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Abstract

Pulmonary hypertension (PH) is a progressive and potentially dangerous, life-threatening disease. A variety of different diseases can be associated with a pathological increase in the average pulmonary artery pressure, hence PH is a very diverse entity. The pathophysiology of PH is extremely variable and complicated. PH may be initiated by factors underlying other diseases. Factors or processes which may often play a key role in the development of PH are genetic predisposition, endothelial dysfunction, vasoconstriction, proliferation, thrombosis, inflammation, and HIV infection. The mechanism of plexogenic pulmonary arteriopathy is not thoroughly understood. However, the primary role belongs to pulmonary endothelial dysfunction.

Keywords

• легочная гипертензия
• медикаментозная терапия
• риоцигуат
• pulmonary hypertension
• drug therapy
• riociguat